David S. Siegel, MD, PhD, at the John Theurer Cancer Center in Hackensack, NJ, explains the benefits of worldwide clinical trials in creating more consistent, less toxic treatment options for multiple myeloma. New drugs are coming along, and the clinical trials for those drugs are beginning to mature.
David S. Siegel, MD, PhDVideo Categories: Hematological Malignancies
Dr. Ajai Chari discusses the ultimate goal of improving therapy for myeloma patients. He mentions the COMPASS study, which is working to collect a database of clinical and scientific information on 1000 patients. In the interim, there are some clues, such as an understanding of certain high-molecular-risk patients and some [ Read More ]
Ajai Chari, MDVideo Categories: Hematological Malignancies
Dr. Vij delves into the role of bioinformatics in identifying targets for drug development.
Ravi Vij, MDVideo Categories: Hematological Malignancies